MARSEILLE, France–(BUSINESS WIRE)–Regulatory Information:

Innate Pharma SA (OTC:) (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Firm) as we speak introduced members of its government group are scheduled to take part within the upcoming convention, detailed beneath. Members will embody Yannis Morel, EVP, Chief Working Officer and Arvind Sood, EVP, President of US Operations.

• BTIG Digital Biotechnology Convention

Dates: August 5 – 6 2024 | Digital

About Innate Pharma

Innate Pharma S.A. is a world, clinical-stage biotechnology firm growing immunotherapies for most cancers sufferers. Its modern method goals to harness the innate immune system by way of therapeutic antibodies and its ANKET ® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

Innate’s portfolio consists of lead proprietary program lacutamab, developed in superior type of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca (NASDAQ:) in non-small cell lung most cancers, in addition to ANKET ® multi-specific NK cell engagers to handle a number of tumor sorts.

Innate Pharma is a trusted associate to biopharmaceutical firms comparable to Sanofi (NASDAQ:) and AstraZeneca, in addition to main research establishments, to speed up innovation, research and improvement for the good thing about sufferers.

Headquartered in Marseille, France with a US workplace in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq within the US.

Be taught extra about Innate Pharma at www.innate-pharma.com and observe us on LinkedIn and X.

Details about Innate Pharma shares

Disclaimer on forward-looking data and threat elements

This press release incorporates sure forward-looking statements, together with these inside the which means of the Personal Securities Litigation Reform Act of 1995. The usage of sure phrases, together with consider, potential, anticipate and can and comparable expressions, is meant to establish forward-looking statements. Though the corporate believes its expectations are based mostly on cheap assumptions, these forward-looking statements are topic to quite a few dangers and uncertainties, which might trigger precise outcomes to vary materially from these anticipated. These dangers and uncertainties embody, amongst different issues, the uncertainties inherent in research and improvement, together with associated to security, development of and outcomes from its ongoing and deliberate medical trials and preclinical research, overview and approvals by regulatory authorities of its product candidates, the Firm’s commercialization efforts and the Firm’s continued capacity to boost capital to fund its improvement. For a further dialogue of dangers and uncertainties which might trigger the corporate’s precise outcomes, monetary situation, efficiency or achievements to vary from these contained within the forward-looking statements, please discuss with the Threat Components (Facteurs de Risque”) part of the Common Registration Doc filed with the French Monetary Markets Authority (AMF), which is obtainable on the AMF web site http://www.amf-france.org or on Innate Pharma’s web site, and public filings and studies filed with the U.S. Securities and Change Fee (SEC), together with the Firm’s Annual Report on Type 20-F for the yr ended December 31, 2023, and subsequent filings and studies filed with the AMF or SEC, or in any other case made public, by the Firm.

This press release and the data contained herein don’t represent a proposal to promote or a solicitation of a proposal to purchase or subscribe to shares in Innate Pharma in any nation.

View supply model on businesswire.com: https://www.businesswire.com/information/residence/20240731971255/en/

For added data, please contact:
Buyers
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr

Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu

Supply: Innate Pharma